.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Fish and Richardson
Citi
QuintilesIMS
Mallinckrodt
Cantor Fitzgerald
Fuji
Daiichi Sankyo
Johnson and Johnson
Teva

Generated: December 14, 2017

DrugPatentWatch Database Preview

King Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for KING PHARMS, and when can generic versions of KING PHARMS drugs launch?

KING PHARMS has twenty-seven approved drugs.

There are seven US patents protecting KING PHARMS drugs.

There are eighty-four patent family members on KING PHARMS drugs in thirty-three countries and seven supplementary protection certificates in six countries.

Summary for King Pharms

International Patents:84
US Patents:7
Tradenames:25
Ingredients:23
NDAs:27
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
King PharmsSYNERCIDdalfopristin; quinupristinINJECTABLE;IV (INFUSION)050748-002Aug 24, 2000DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
King Pharms LlcCORZIDEbendroflumethiazide; nadololTABLET;ORAL018647-002May 25, 1983ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
King Pharms LlcTAPAZOLEmethimazoleTABLET;ORAL040320-001Mar 31, 2000ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-002Mar 20, 2002DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
King PharmsCYTOMELliothyronine sodiumTABLET;ORAL010379-002Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
King PharmsCYTOMELliothyronine sodiumTABLET;ORAL010379-003Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
King Pharms LlcTAPAZOLEmethimazoleTABLET;ORAL040320-002Mar 31, 2000ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
King PharmsLEVOXYLlevothyroxine sodiumTABLET;ORAL021301-006May 25, 2001AB1,AB3RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
King Pharms LlcALTACEramiprilCAPSULE;ORAL019901-004Jan 28, 1991ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
King PharmsLEVOXYLlevothyroxine sodiumTABLET;ORAL021301-012May 25, 2001DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for King Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms LlcALTACEramiprilCAPSULE;ORAL019901-002Jan 28, 1991► Subscribe► Subscribe
King Pharms LlcALTACEramiprilCAPSULE;ORAL019901-001Jan 28, 1991► Subscribe► Subscribe
King Pharms LlcTILADEnedocromil sodiumAEROSOL, METERED;INHALATION019660-001Dec 30, 1992► Subscribe► Subscribe
King Pharms LlcALTACEramiprilCAPSULE;ORAL019901-003Jan 28, 1991► Subscribe► Subscribe
King Pharms LlcCORZIDEbendroflumethiazide; nadololTABLET;ORAL018647-002May 25, 1983► Subscribe► Subscribe
King Pharms LlcALTACEramiprilCAPSULE;ORAL019901-001Jan 28, 1991► Subscribe► Subscribe
King Pharms LlcCORZIDEbendroflumethiazide; nadololTABLET;ORAL018647-002May 25, 1983► Subscribe► Subscribe
King Pharms LlcCORZIDEbendroflumethiazide; nadololTABLET;ORAL018647-001May 25, 1983► Subscribe► Subscribe
King Pharms LlcAVINZAmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL021260-006Dec 18, 2008► Subscribe► Subscribe
King PharmsPROCANBIDprocainamide hydrochlorideTABLET, EXTENDED RELEASE;ORAL020545-002Jan 31, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for KING PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
morphine sulfateExtended-release Capsules45 mg and 75 mgAVINZA7/30/2009
morphine sulfateExtended-release Capsules30 mg, 60 mg, 90 mg and 120 mgAVINZA6/4/2007
metaxaloneTablets800 mgSKELAXIN11/4/2004

Non-Orange Book Patents for King Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,378,434Metaxalone products, method of manufacture, and method of use► Subscribe
6,683,102 Methods of using metaxalone in the treatment of musculoskeletal conditions► Subscribe
6,407,128 Method for increasing the bioavailability of metaxalone► Subscribe
8,168,664Metaxalone products, method of manufacture, and method of use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for King Pharms Drugs

Country Document Number Estimated Expiration
Spain2199378► Subscribe
Bulgaria65474► Subscribe
New Zealand530702► Subscribe
World Intellectual Property Organization (WIPO)9920255► Subscribe
Yugoslavia8502► Subscribe
Japan2003527325► Subscribe
Canada2488370► Subscribe
Ukraine77151► Subscribe
South Africa9809463► Subscribe
Serbia50377► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for King Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0001Belgium► SubscribePRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
80030Netherlands► SubscribePRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
13/055Ireland► SubscribePRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
323Luxembourg► SubscribePRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
C0062France► SubscribePRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
C/GB98/047United Kingdom► SubscribePRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
C/GB03/034United Kingdom► SubscribePRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Moodys
Daiichi Sankyo
Argus Health
Queensland Health
Covington
Colorcon
Boehringer Ingelheim
Fish and Richardson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot